

# ASCO® Exhibitor Newsletter



Stay up to date on the latest ASCO® exhibits news, including exhibit and advertising opportunities, policy updates, and more. Encourage your colleagues to [sign up](#) to receive this monthly newsletter.

## TABLE OF CONTENTS

- [The Time is NOW for ASCO GI and GU Cancers Symposia in San Francisco, CA](#)
- [Payment Deadline Approaching: ASCO Annual Meeting](#)
- [Best of ASCO® Flagship Meeting Scheduled for Seattle](#)
- [The Can't-Miss Global Clinical Care Conference in 2023: ASCO Breakthrough](#)
- [Put those 2023 Advertising Dollars to Use!](#)
- [ASCO Plenary Series: Publish and Present Your Research Within Two Months](#)

### The Time is NOW for ASCO GI and GU Cancers Symposia in San Francisco, CA

We are excited to welcome many of you to San Francisco, CA for [#GI23](#) this week and [#GU23](#) next month. What to expect:

- Dynamic and interactive sessions
- Enhanced opportunities for face-to-face networking
- Innovative in-person exhibits
- On-demand access to meeting materials

### Payment Deadline Approaching: ASCO Annual Meeting

We are looking forward to welcoming attendees back to the Windy City in June. Please note these upcoming deadlines:

- **Final Payment Due:** The final payment for the 2023 ASCO Annual Meeting is due by Friday, January 27. Don't miss out on the opportunity to earn 1 of 2 payment priority points for the 2024 Space Selection. Companies who fail to pay may lose their space on the floor. Contact [ascoexhibits@spargo.com](mailto:ascoexhibits@spargo.com) with questions.
- **Abstract Submissions:** The deadline to submit abstracts for the 2023 ASCO Meeting is February 14, 2023. Review guidelines, policies, and submission categories in our [Call for Abstracts Booklet](#).
- **Hotel Reservations & Registration:** Registration and Hotel Reservations are currently open. For more information or to register and reserve a hotel, visit the [Exhibitor Registration and Hotels](#) page. The Hotel Reservation and Early Registration Deadline is Wednesday April 26, 2023.

### Best of ASCO® Flagship Meeting Scheduled for Seattle

ASCO is excited to announce the biggest Best of ASCO Meeting yet. The meeting will be held July 21-22 in Seattle, WA and review the most practice-changing research presented during the 2023 ASCO Annual Meeting. The meeting will focus on relevance to clinical practice, as well as implications for future research. Exhibit sales will begin in early March. Stay tuned for details.

### The Can't-Miss Global Clinical Care Conference in 2023: ASCO Breakthrough

ASCO Breakthrough is THE can't miss global clinical cancer conference of 2023! The meeting, scheduled for August 3-5, 2023 in Yokohama, Japan, will

- Feature high-impact, novel research put into real-world clinical context
- Showcase global oncology thought leaders and pioneers
- Offer opportunities for collaboration
- Provide solutions, and...
- Leave you inspired!

#### Don't Miss It!

Keep your eyes out for exhibit, advertising, and support opportunities coming out in early February. Learn more about the [program](#) and contact [Michele LaFrance](#) for additional information.

#### Put those 2023 Advertising Dollars to Use!

Get your company and/or product in front of a global audience and leave a lasting impression. In-person, print, digital and more opportunities are available. Please contact [Jen Callow](#) with AMC Media group at 732-580-8884 for more information.

- [GU Media Kit](#)
  - *ASCO Daily News* Premium Positions are still available but selling fast. Act NOW as the deadline is quickly approaching!
- [2023 Media Kit](#)
  - *ASCO Connection*, *ASCO Annual Meeting*, *ASCO Quality Care Symposium* and MORE!

#### ASCO Plenary Series: Publish and Present Your Research Within Two Months

Do you have clinical trial results ready to share that will impact cancer therapy? Your research could be the next headline! The [ASCO Plenary Series](#) brings breaking cancer science year-round to a global oncology audience. The results of an important randomized phase II trial for non-small cell lung cancer (NSCLC) were presented during [December's session](#). In the trial, researchers evaluated whether inhibition of TIGIT and adenosine pathways augments the activity of zimberelimab in patients with first-line, metastatic, PD-L1-high NSCLC. The presentation is available to watch on demand at no charge. Maximize the visibility of your research. [Submit](#) for March's session by February 7.



[ASCO Exhibitor Policies](#)



[Contact Us](#)



[Upcoming Meetings](#)

Follow us:



Click [here](#) to unsubscribe.



SPARGO, Inc.

11208 Waples Mill Road, Suite 112, Fairfax, VA 22030